Research field (3):
Tumor diagnostics and therapeutics
, Gastroenterology
, Tumor biology
Research keywords (4):
Clinical Oncology
, Cancer Genome Profiling
, Cancer Stem Cell
, Cancer Chemotherapy
Research theme for competitive and other funds (3):
2022 - 2025 CDKN3 inhibitor as a new compound to overcome the resistance to cytotoxic chemotherapy
2019 - 2022 CDKN3 as a new target of anti-cancer treatment overcoming the resistance to cytotoxic chemotherapy
2016 - 2018 The mechanism of chemotherapy resistance in colon cancer stem cells and epithelial mesenchymal transition colon cancer cells
Papers (50):
Shogo Yamamura, Masashi Kanai, Yasuhide Takeuchi, Natsuko Okita, Tomohiro Kondo, Masahiro Yoshioka, Junichi Matsubara, Shigemi Matsumoto, Manabu Muto. Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring MET amplification. International cancer conference journal. 2024. 13. 2. 83-87
Trang H. Nguyen Vu, Osamu Kikuchi, Shinya Ohashi, Tomoki Saito, Tomomi Ida, Yukie Nakai, Yang Cao, Yoshihiro Yamamoto, Yuki Kondo, Yosuke Mitani, et al. Combination therapy with WEE1 inhibition and trifluridine/tipiracil against esophageal squamous cell carcinoma. Cancer Science. 2023. 114. 12. 4664-4676
Junichi Matsubara, Kumi Mukai, Tomohiro Kondo, Masahiro Yoshioka, Hidenori Kage, Katsutoshi Oda, Ryo Kudo, Sadakatsu Ikeda, Hiromichi Ebi, Kei Muro, et al. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities. JAMA Network Open. 2023. 6. 7. e2323336-e2323336
Tomohiro Kondo, Masashi Kanai, Junichi Matsubara, Daisuke Yamaguchi, Takashi Ura, Tadayuki Kou, Toshinao Itani, Motoo Nomura, Taro Funakoshi, Akira Yokoyama, et al. Association between homologous recombination gene variants and efficacy of oxaliplatin-based chemotherapy in advanced pancreatic cancer: prospective multicenter observational study. Medical oncology (Northwood, London, England). 2023. 40. 5. 144-144
Yohei Chiba, Kazuki Sudo, Yuki Kojima, Hitomi Okuma, Shinji Kohsaka, Ryunosuke Machida, Masahiko Ichimura, Kenta Anjo, Kazumi Kurishita, Natsuko Okita, et al. A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial. BMC Cancer. 2022. 22. 1
2009 - American Association for Cancer Research Scholar-in-Training Award
Show all
Association Membership(s) (9):
The Molecular Biology Society of Japan
, American Society of Clinical Oncology (ASCO)
, American Association for Cancer Research (AACR)
, 日本胃癌学会
, 日本癌治療学会
, 日本癌学会
, 日本臨床腫瘍学会
, 日本消化器病学会
, 日本内科学会